Get the Stockscreener App
10.04
1.08%
-0.11
Pre-market:
10.07
0.03
+0.30%
Roivant Sciences Ltd stock is traded at $10.04, with a volume of 5.27M.
It is down -1.08% in the last 24 hours and down -6.95% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$10.15
Open:
$10.15
24h Volume:
5.27M
Relative Volume:
0.93
Market Cap:
$7.27B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
1.777
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
-1.47%
1M Performance:
-6.95%
6M Performance:
-13.60%
1Y Performance:
-4.02%
1-Day Range:
$10.01
$10.32
1-Week Range:
$9.895
$10.32
52-Week Range:
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Compare ROIV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
10.04 | 7.27B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Immunovant makes leadership changes - MSN
Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus - insights.citeline.com
Cantor Fitzgerald maintains overweight on Roivant Sciences stock By Investing.com - Investing.com South Africa
Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications - marketscreener.com
When (ROIV) Moves Investors should Listen - news.stocktradersdaily.com
Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance
Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In - Insider Monkey
Immunovant, Roivant slip after trial data for autoimmune disorder therapy - MSN
Knott David M Jr Decreases Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
KLP Kapitalforvaltning AS Invests $918,000 in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
ROIV stock touches 52-week low at $9.96 amid market fluctuations By Investing.com - Investing.com South Africa
ROIV stock touches 52-week low at $9.96 amid market fluctuations - Investing.com Australia
Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Loomis Sayles & Co. L P Has $43.43 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 315,522 Shares of Stock - MarketBeat
Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Insider Monkey
Roivant Sciences president Eric Venker sells shares worth $8.19 million By Investing.com - Investing.com UK
Roivant Sciences president Eric Venker sells shares worth $8.19 million - Investing.com
(ROIV) Trading Advice - news.stocktradersdaily.com
Roivant Sciences finalizes consulting agreement with former officer - Investing.com India
Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned - insights.citeline.com
Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint -March 19, 2025 at 08:24 am EDT - Marketscreener.com
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
Critical Clinical Data Coming: Roivant's Dual Breakthrough Results in MG and CIDP Studies - Stock Titan
(ROIV) Trading Signals - Stock Traders Daily
Wall Street Analysts Believe Montes Archimedes Acquisition (ROIV) Could Rally 60%: Here's is How to Trade - Nasdaq
Roivant at Leerink’s Conference: Strategic Insights and Developments By Investing.com - Investing.com Australia
Does Roivant (ROIV) Offer an Attractive Risk Reward Opportunity? - Insider Monkey
Genevant and Arbutus initiate patent lawsuit against Moderna - The Pharma Letter
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Roivant Sciences Ltd. (ROIV): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by New York State Common Retirement Fund - Defense World
Trend Tracker for (ROIV) - Stock Traders Daily
Principal Financial Group Inc. Lowers Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Handelsbanken Fonder AB Trims Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Net worth of Vivek Ramaswamy: Roviant Sciences founder who is running for Ohio governor - Times of India
Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board - The Manila Times
Early Warning Report Issued Pursuant to National Instrument 62?103: Roivant announces Resignation and Replacement of Arbutus Board - Lelezard
Key milestones in Vivek Ramaswamy’s academic journey: From being a Valedictorian to a member of Harvard P - Times of India
Roivant Sciences president Eric Venker sells $1.07 million in shares - Investing.com India
Roivant Sciences appoints new Principal Accounting Officer By Investing.com - Investing.com South Africa
Roivant Sciences appoints new Principal Accounting Officer - Investing.com
Roivant Sciences Appoints New Chief Accounting Officer - TipRanks
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):